## Optimal Therapy Scheduling Based on a Pair of Collaterally Sensitive Drugs

Nara Yoon, Robert Vander Velde, Andriy Marusyk and Jacob G. Scott

October 13, 2017

#### Abstract

Despite major strides in the treatment of cancer, the development of drug resistance remains a major hurdle. To address this issue, researchers have proposed sequential drug therapies with which the resistance developed by a previous drug can be relieved by the next one, a concept called collateral sensitivity. The optimal times of these switches, however, remains unknown.

We therefore developed a dynamical model and study the effect of sequential therapy on heterogeneous tumors comprised of resistant and sensitivity cells. A pair of drugs (DrugA, DrugB) are utilized and switched in turn within the therapy schedule. Assuming that they are collaterally sensitive to each other, we classified cancer cells into two groups, and explored their population dynamics:  $A_R$  and  $B_R$ , each of which is subpopulation of cells resistant to the indicated drug and concurrently sensitive to the other.

Based on a system of ordinary differential equations for  $A_R$  and  $B_R$ , we determined that the optimal treatment strategy consists of two stages: initial stage in which a chosen better drug is utilised until a specific time point, T, and afterward; a combination of the two drugs with relative durations (i.e.  $f\Delta t$ -long for DrugA and  $(1 - f)\Delta t$ -long for DrugB with  $0 \le f \le 1$ and  $\Delta t \ge 0$ ). Of note, we prove that the initial period, in which the first drug is administered, T, is shorter than the period in which it remains effective in lowing total population, contrary to current clinical intuition.

We further analyzed the relationship between population makeup,  $ApB = A_R/B_R$ , and effect of each drug. We determine a specific makeup,  $ApB^*$ , at which the two drugs are equally effective. While the optimal strategy is applied, ApB is changing monotonically to  $ApB^*$  and then remains at  $ApB^*$  thereafter.

25 26 27

28

29

1

2

3

л

5 6

7

8

9

10

11

12 13

14

15

16

17

18

19

20 21

22

23

24

Beyond our analytic results, we explored an individual based stochastic model and presented the distribution of extinction times for the classes of solutions found. Taken together, our results suggest opportunities to improve therapy scheduling in clinical oncology.

## **30 1 Introduction**

Drug resistance is observed in many patients after exposure to cancer therapy, and is a major hurdle in the cancer therapy [1]. Treatment with appropriate chemo- or targeted therapy reliably reduces tumor burden upon initiation. However, resistance inevitably arises, and disease burden relapse [2]. The disease recurrence is visible, at the earliest, when disease burden reaches a threshold of detection, at which first therapy is considered failed and a second line drug is used, to control the disease

in more efficient way (see Figure 1 (a)). Redesign of treatment is required to start earlier than the time point, not only because the detection threshold is higher than the minimum disease burden, but also because first drug could become less efficient as duration of therapy reaches to  $T_{max}$ . In this research, we focus on the latter reason and figure out how much earlier we should switch drug in advance of  $T_{max}$ , assuming that the former reason is less important  $(t_{DT} - t_o \approx T_{max})$ .

41

In preexisting tumor, both resistant and sensitive types of cells against a therapy are thought to co-exist even before the beginning of the therapy [3], and the cellular composition is shaped according to choices of drugs (diagrammed at Figure 1 (b)). Such alteration of cell populations is toward gaining resistant properties against the drug being administered, due to (i) kinetic changes affecting DNA synthesize during S-phase [4], (ii) drug induced genetic (point) mutations [5], or (iii) phenotypic plasticity and resulting epigenetic modifications [6].

48

To deal with the resistance developed by a drug, one can prescribe a different drug as a follow-49 up therapy targeting the resistance issue. Researchers have sought specific combinations that induce 50 sensitivity, this is the concept of collateral sensitivity [7, 8, 9]. In specific cases, an order of several 51 drugs complete a collateral sensitivity cycle [8], and corresponding periodic drug sequence can be 52 used in prescription of a long term therapy - though we recently showed that the continued effi-53 cacy of the same cycle is not guaranteed [10]. In this research, we focused on such drug cycling 54 comprised by just two drugs, each of which can be used as a targeted therapy treating non-cross 55 resistant factors occurring after the therapy of the other drug (diagrammed on Figure 1 (b)). 56 57




Figure 1: (a) General dynamical pattern of disease burden. It increases initially and then decreases as of the therapy starting point  $(t_0)$ , and eventually rebounds after the maximum period with positive therapy effect  $(T_{max})$ . Relapse is found, at the earliest, when disease burden reaches detection threshold at  $t_{DT}$ . (b) Change in composition of tumor cell population when a pair of collaterally sensitive drugs are given one after another.

<sup>58</sup> The underlying dynamics of resistance development has been studied by looking cell popula-

tions mixed by sensitive and resistant types against therapy/therapies, whether it is genotypic or 59 phenotypic classifications [11]. Additionally, many researchers have accounted for their choices of 60 detailed cellular heterogeneities like: (i) stages in evolutionary structures [12, 13], (ii) phases of 61 cell cycle [14, 15, 16, 17], or (iii) spatial distribution of irregular therapy effect [18, 19]. Among 62 them, many researches (including [11, 15, 16, 20, 21]) studied the effect of a pair of non-cross 63 resistant drugs like us, using the Goldie-Coldman model or its variations [12, 21, 22, 23]. Those 64 models are basically utilizing population structure of four compartments each of which represents 65 subpopulation (i) sensitive to the both drugs, (ii) and (iii) resistant to one of them respectively, or 66 (iv) resistant to both. 67

68

In this research, we want to propose a simpler modeling structure including only two types of subpopulations (see Section 2 for the detail), which is still appropriate in the study of collaterally sensitive drug effect and whose simplicity facilitates mathematical derivations of interesting concepts and quantities (see Section 3 for the detail of the analytical derivations). The model we propose at Section 2 has a potential to be expanded with other important considerations as well, like comparable stochastic simulations described in Section 4 and other future works explained in Section 5.

## 76 2 Modeling setup

#### 77 2.1 Basic cell population dynamics under a single drug administration

<sup>78</sup> Before describing the comprehensive model for collateral sensitive network in Section 2.2, let us <sup>79</sup> go over a fundamental modeling structure describing dynamical behavior of cell populations under <sup>80</sup> a single drug. Based on the sensitivity and resistance to the therapy, cell population can be split <sup>81</sup> into two groups. Then, we call the populations of the sensitive cells and the resistant cells by  $C_S$ <sup>82</sup> and  $C_R$  respectively, and use total cell population,  $C_P = C_S + C_R$ , in measuring disease burden <sup>83</sup> and drug effect.

84

90

We account three dynamical events in our model: proliferation of sensitive (s) and resistant cells (r), and transition between the cell types (g). Here, net proliferation rate represents combined birth and death rate, so can be positive if birth rate is higher than death rate or negative otherwise. It is reasonable to assume that, under the presence of drug, sensitive cell population declines (s < 0), resistant cell population increases (r > 0), and g > 0 for transition.

$$s \begin{pmatrix} C_S \\ g \end{pmatrix} = \begin{pmatrix} -(g-s) & 0 \\ g & r \end{pmatrix} \begin{pmatrix} C_S \\ C_R \end{pmatrix}$$
(1)

Figure 2: Diagram of dynamics between sensitive cells population,  $C_S$ , and resistant cells population,  $C_R$ , (on the left panel) and the differential system of  $\{C_S, C_R\}$  (on the right panel) with s-proliferation rate of sensitive cells, r-proliferation rate of resistant cells, g-transition rate from  $C_S$  to  $C_R$ 

Figure 2 shows the diagrams of such population dynamics, and the system of ordinary differential equations that  $\{C_S, C_R\}$  obey. The solution of the system (1) is

$$\begin{pmatrix} C_S(t) \\ C_R(t) \end{pmatrix} = \begin{pmatrix} e^{-(g-s)t} & 0 \\ \frac{g(e^{rt} - e^{-(g-s)t})}{g+r-s} & e^{rt} \end{pmatrix} \begin{pmatrix} C_S^0 \\ C_R^0 \end{pmatrix}$$
(2)

where  $\{C_S(0), C_R(0)\} = \{C_S^0, C_R^0\}$ . By (2), total population is

$$C_P(t) = \left(\frac{r-s}{g+r-s}C_S^0\right)e^{-(g-s)t} + \left(\frac{g\left(C_S^0 + C_R^0\right) + (r-s)C_R^0}{g+r-s}\right)e^{rt}.$$
(3)

95 96

 $C_P(t)$  is a positive function comprised of a linear combination of exponential growth  $(e^{r t})$  and exponential decay  $(e^{-(g-s) t})$  with positive coefficients. Despite the limitations of simple exponential growth models [24], we feel it is a reasonable place to start, since the relapse of tumor size starts when it is much smaller than its carrying capacity which results in almost exponential growth.

 $C_P$  has one and only one minimum point in  $\{-\infty, \infty\}$ , after which  $C_P$  increases monotonically. If  $C'_P(0) = s C^0_S + r C^0_R \ge 0$ , the drug is inefficient.  $(C_P(t)$  is increasing on  $t \ge 0$ , see an example on Figure 3 (a)) Otherwise, if  $C'_P(0) < 0$ , the drug is effective in reducing tumor burden at the beginning, although it will eventually regrow (drug resistance; see an example on Figure 3 (b)).




Figure 3: Representative population histories of sensitive and resistant cells and their summation with initial population makeup,  $\{C_S^0, C_R^0\} = \{0.9, 0.1\}$ . (a) increasing total population with  $\{s, r, g\} = \{-0.01, 0.1, 0.001\}; C'_P(0) = 0.001 > 0$ . (b) rebounding total population with  $\{s, r, g\} = \{-0.09, 0.08, 0.001\}; C'_P(0) = -0.073 < 0$ .

#### <sup>106</sup> 2.2 Cell population dynamics with a pair of collateral sensitivity drugs

Here, we describe the effect of a combined therapy with two drugs switched in turn, by extending the model for a single-drug administration (System (1)). Assuming that the drugs are collaterally sensitive to each other, cell population is classified into just two groups reacting to the two types of drugs in opposite ways. Depending on which drug to be administered, cells in the two groups will have different proliferation rates and direction of cell-type transition (see Figure 4). That is, the population dynamics of the two groups follow a piecewise continuous differential system consisting of a series of the system (1), each of which is assigned on a time slot bounded by times of

114 drug-switch.

115

	Proliferat- ion of $A_R$	Transition	Proliferat- ion of $B_R$
Drug A	$r_A \downarrow A_R \downarrow g_A B_R \downarrow s_A$		
Drug B	$s_B \subsetneq A$	$R \xrightarrow{g_B} E$	$B_R$ $r_B$

Figure 4: Population dynamics between  $A_R$  – population of cells resistant only to DrugA and  $B_R$  – population of cells resistant only to DrugB under the presence of DrugA, or DrugB. For each drug therapy, three drug-parameters of proliferations (colored red and green) and transition (colored blue) are involved.

<sup>116</sup> In summary, we assume that

117	• there is a pair of collaterally sensitive drugs, $DrugA$ and $DrugB$ , which are characterized
118	by their own model parameters, $p_A = \{s_A, r_A, g_A\}$ and $p_B = \{s_B, r_B, g_B\}$ respectively,

• cell population can be split into two subpopulations,  $A_R$  - resistant to DrugA and at the same time sensitive to DrugB, and  $B_R$  - resistant to DrugB and sensitive to DrugA, and

• three types of factors determine the dynamical patterns, (i) drug parameters,  $\{p_A, p_B\}$ , (ii) initial population ratio  $ApB_0 = A_R(0)/B_R(0)$  (assuming that  $A_R(0) + B_R(0) = 1$ ), and (iii) drug switch schedule.

<sup>124</sup> An example of histories of  $\{A_R, B_R, A_R + B_R\}$  with a choice of the three factors is shown at <sup>125</sup> Figure 5.

### **3** Analysis on therapy scheduling

#### 127 **3.1** Drug-switch timing

We explored possible strategies on choosing drug switch timing within our modeling setup. The first idea is relevant to clinical intuition: switching drug at the global minimum point of tumor size  $(T_{max}; \text{ see Figure 1 (a)})$ , which is shown to exist uniquely in the previous section if and only if  $C_R(0)/C_S(0) < -s/r$ . The expression of  $T_{max}$  derived from our model is

$$T_{max}(\{s,r,g\}, RpS_0) = \frac{\ln\left[\frac{(g-s)(r-s)}{r(g(RpS_0+1)+RpS_0(r-s))}\right]}{g+r-s} \qquad \text{with } RpS_0 = \frac{C_R(0)}{C_S(0)}.$$
 (4)

 $T_{max}$  depends on (i) the parameters of drug being administered, and (ii) initial population makeup. In the DrugA-based therapy, it is  $T_{max}(p_A, ApB_0)$ , and in the DrugB-based therapy, it is  $T_{max}(p_B, 1/ApB_0)$ .




Figure 5: Representative plots describing dynamics of cell populations resistant to DrugA ( $A_R$ ), resistant to DrugB ( $B_R$ ) and total ( $A_R + B_R$ ) during drug switches. Here,  $p_A = p_B = \{-0.9, 0.08, 0.1\}/day$  and  $\{A_R^0, B_R^0\} = \{0.5, 0.5\}$ .

In addition to  $T_{max}$ , another time point with significant meaning is  $T_{min}$ , explained below. Since the decreasing rate is almost zero around  $T_{max}$  with no switch (see the black curve of Figure 5), we seek to find a way to expedite the decreasing rate by switching drug before  $T_{max}$ . To decide how much earlier to do so, we compared the derivative of  $A_R + B_R$  under constant selective pressure (no switch) at an arbitrary time point,  $t_1$ , and compared it to the right derivative of  $A_R + B_R$  with the drug-switch assigned at  $t_1$ . For example, if the first drug is DrugA and the follow-up drug is DrugB, we compared

$$C'_{P}(t_{1} \text{ given } \{s, r, g\} = p_{A} \text{ and } \{C^{0}_{S}, C^{0}_{R}\} = \{B_{R}(t_{1}), A_{R}(t_{1})\}) \text{ from (3),}$$

143 and

144

149

142

$$C'_P(t_1 \text{ given } \{s, r, g\} = p_B \text{ and } \{C^0_S, C^0_R\} = \{A_R(t_1), B_R(t_1)\}) \text{ also from (3)}.$$

This comparison reveals that the two derivatives are equal at a specific point (this is  $T_{min}$ , see the yellow curve on Figure 6), the derivative of drug-switch is lower (higher in absolute value; higher decreasing rate) if  $t_1 > T_{min}$  (see the blue and green curves on Figure 6), and the derivative of no-switch is lower if  $t_1 < T_{min}$  (see the red curve on Figure 6).

 $T_{min}$  depends on the parameters for the first drug  $\{s_1, r_1, g_1\}$  and for the second drug  $\{s_2, r_2\}$ , and initial population ratio between resistant cells and sensitive cells for the first drug  $RpS_0$ . Here, transition parameter of second drug  $(g_2)$ , and respective values of the two populations are unnecessary in the evaluation of  $T_{min}$ , which is found to be

$$T_{min}(\{s_1, r_1, g_1\}, \{s_2, r_2\}, RpS_0) = \frac{\ln\left[\frac{(r_1 - s_1)(r_2 - s_1) + g_1(r_1 + r_2 - s_1 - s_2)}{(r_1 - s_2)(g_1 + RpS_0(g_1 + r_1 - s_1))}\right]}{g_1 + r_1 - s_1}.$$
 (5)

In DrugA-to-DrugB switch, it is  $T_{min}(p_A, p_B, ApB_0)$ , and in DrugB-to-DrugA switch, it is  $T_{min}(p_B, p_A, 1/ApB_0)$ .

156




Figure 6: Comparison of total population curves with one-time drug-switch from DrugA to DrugB at different time points, (i) at  $T_{min}$  (worse than without-switch; red curve), (ii) at  $T_{min}$  (same as without-switch; yellow curve), (iii) between  $T_{min}$  and  $T_{max}$  (better than without-switch; green curve), and (iv)  $T_{max}$  (better than without-switch; blue curve). Each color of dot/curve represents cell population level on and after drug-switch of each switching strategy. The dashed curve mixed by yellow and black colors represent the yellow and black curves overlapped. Parameters:  $p_A = p_B = \{-0.9, 0.08, 0.001\}/day$  and  $\{A_R^0, B_R^0\} = \{0.1, 0.9\}$ .

An important issue observed in Figure 6 is that the population curve with only one-time drug-157 switch after  $T_{min}$  (and before  $T_{max}$ , assuming that  $T_{min} < T_{max}$ ) is not guaranteed to be lower 158 than that of one-time switch at  $T_{max}$  over an entire time range. (i.e., the green curve relevant to the 159 switch at  $(T_{min} + T_{max})/2$  and the blue curve relevant to the switch at  $T_{max}$  intersect at  $t \approx 58$  and 160 the blue curve is lower after the time of the intersection). However, sequential drug switches started 161 between  $T_{min}$  and  $T_{max}$  leave a possibility of finding a better drug schedule than the  $T_{max}$ -based 162 strategy. Figure 7 shows possible choices of follow up switches (green and black curves) which 163 achieve better results than  $T_{max}$ -switch (red curves), unlike the drug-switches started before  $T_{min}$ 164 remaining less effective (magenta curve). 165


166

Optimal drug switch scheme will be discussed in detail in Section 4.2. The optimal scheduling for the example of Figure 5 starts with the first drug until  $T_{min}$  (blue curve for  $0 < t \leq T_{min}$ ) followed by rapid exchange of the two drugs afterward (black curve for  $t > T_{min}$ ). Switching before  $T_{max}$ , that is, before the drug has had its full effect, goes somewhat against clinical intuition, and is therefore an opportunity for unrealized clinical improvement based on a rationally scheduled switch at  $T_{min}$ . In order to realize this however, there are conditions about the order of  $T_{max}$  and  $T_{min}$  which must be satisfied. In particular:

$$\begin{cases}
T_{min} < T_{max} \text{ if and only if } r_A r_B < s_A s_B \\
T_{min} = T_{max} \text{ if and only if } r_A r_B = s_A s_B \\
T_{min} > T_{max} \text{ if and only if } r_A r_B > s_A s_B.
\end{cases}$$
(6)

In our analysis and simulations, we will deal with the cases mostly satisfying  $r_A r_B < s_A s_B$ , as otherwise we cannot expect improvement of clinical strategy using  $T_{min}$ , and more importantly as the choice of drugs not satisfying  $r_A r_B < s_A s_B$  is not powerful to reduce cell population (explained in detail in the next section and Figure 8).

178



- After DrugA-to-DrugB switch at t=T<sub>max</sub>
- Instantaneous switch starting at (i) t=0 and (ii) t=T<sub>min</sub>
- Arbitrary schedule with initial DrugA-to-DrugB switch earlier than T<sub>min</sub>
- Arbitrary schedule with initial DrugA-to-DrugB switch between T<sub>min</sub> and T<sub>max</sub>

Figure 7: Total population curves with different therapy strategies with  $p_A = p_B = \{-0.9, 0.08, 0.001\}/day$  and  $\{A_R^0, B_R^0\} = \{0.1, 0.9\}$  (a) full range of relative population (b) enlargement of the shaded areas on (a)

The difference between  $T_{min}$  and  $T_{max}$  ( $T_{gap}$ ), provides intuition on how much shorter the first drug administered than it is used to be.

$$T_{gap}(\{s_1, r_1, g_1\}, \{s_2, r_2\}) := T_{max}(\{s_1, r_1, g_1\}, RpS_0) - T_{min}(\{s_1, r_1, g_1\}, \{s_2, r_2\}, RpS_0)$$
$$= \frac{\ln\left[\frac{(g_1 - s_1)(r_1 - s_1)(r_1 - s_2)}{r_1((r_1 - s_1)(r_2 - s_1) + g_1(r_1 + r_2 - s_1 - s_2))}\right]}{g_1 + r_1 - s_1}$$
(7)

We studied sensitivity analysis on  $T_{gap}$  over a reasonable space of non-dimentionalized drug parameters in Appendix B. Expectedly, as the proliferation rates under the second drugs increases  $(r_2 \uparrow \text{ and/or } s_2 \uparrow)$ , the optimal switching timing to the second drug is delayed  $(T_{min} \uparrow \text{ and } T_{gap} \downarrow)$ . As  $r_1$  increases, both  $T_{min}$  and  $T_{max}$  decrease. However,  $T_{max}$  decrease more than  $T_{min}$  does, so in overall  $T_{gap}$  decreases.  $s_1$  and  $T_{gap}$  do not have a monotonic relationship.  $T_{gap}$  is increasing as  $s_1$  is increasing in a range of relatively low values, but it turns into decreasing in relatively high values of  $s_1$ .

#### **3.2** Population makeup and drug effect

192

In this section, we study how the degree of cellular heterogeneity and therapy effect are related, and checked the roles of  $T_{min}$  and  $T_{max}$  in the relationships. We defined a function of population makeup ApB based on the ratio between the two cell types,

$$ApB(t) := rac{A_R(t)}{B_R(t)}$$

Then, the ratio at  $T_{min}$  with DrugA-to-DrugB switch  $(T_{min}^A)$  and with DrugB-to-DrugA switch  $(T_{min}^B)$  are equivalent.

$$ApB(T_{min}^{A}) = ApB(T_{min}^{B}) = \frac{r_{B} - s_{A}}{r_{A} - s_{B}} := ApB^{*}.$$
(8)

195 At  $T_{max}$  with  $DrugA(T_{max}^A)$ , and with  $DrugB(T_{max}^B)$ , we have

196

203

$$ApB(T_{max}^A) = \frac{-s_A}{r_A}, ApB(T_{max}^B) = \frac{r_B}{-s_B},$$

And, as s < 0 and r > 0, those values of ApB are all positive.

We next consider the level of drug effect at each ApB by taking the derivative of cell population under the presence of the drug. Fixing the total population, the derivative is defined by ApBin addition to the model parameters. We define this effect by

$$Ef(ApB) := \left. \frac{d}{dt} (A_R(t) + B_R(t)) \right|_{t=0, ApB_0 = ApB}^{p_A \text{ or } p_B} \text{ with } A_R(0) + B_R(0) = 1.$$

The effects of DrugA (specified by  $p_A$ ) and DrugB (specified by  $p_B$ ) defined in this way are equivalent at  $ApB^*$ , by the definitions of  $T_{min}$  and  $ApB^*$ . The effect of DrugA is larger if  $ApB < ApB^*$ , since the cell population resistant to DrugA is relatively smaller than the population of the other cell type. Otherwise, DrugB has a better effect. At the makeup of  $T^A_{max}$ , DrugA has no effect on population reduction. If ApB is getting smaller than that, DrugA becomes effective. And, the smaller ApB is, the better effect DrugA has. Similarly the effect of Drug B is zero at  $ApB(T^B_{max})$ and increases as ApB increases above  $ApB(T^B_{max})$  (see Figure 8).




Figure 8: Effect of DrugA and DrugB over the axis of ApB. The two drugs have same effect at  $ApB = ApB^*$ , and have no effect at  $ApB = -s_A/r_A$  (in case of DrugA) or  $ApB = -r_B/s_B$  (in case of DrugB). The drug effect is getting bigger, as ApB is getting farther from the no-effect level to the direction of getting less cell population resistant to the drug.

The population makeup changes in the opposite direction. As DrugA (or DrugB) therapy continues, ApB continues to increase (or decrease). So, if DrugA (or DrugB) is given too long, it should go through a period of no or almost no effect around  $ApB = -s_A/r_A$  (or around  $ApB = -r_B/s_B$ ), but once the drug is switched after that, there will be a higher therapy effect with DrugB (or with DrugA). Such two opposite aspect has shown to be balanced by switching drug when the population makeup reaches  $ApB^*$ .

218

Depending on the condition (6), the order of the three ratios at  $T_{min}$ ,  $T_{min}^A$  and  $T_{max}^B$  changes. In particular, if  $r_A r_B < s_A s_B$ , there exists an interval of ApB,  $(-r_B/s_B, -s_A/r_A)$ , in which both drugs are effective in decreasing population, given the condition is satisfied. Otherwise, if  $r_A r_B < s_A s_B$ , no drug is effective when  $ApB \in (-s_A/r_A, -r_B/s_B)$ . These results are schematized in Figure 8.

224

#### **3.3** Optimal scheduling and its clinical implementation

In this sections, we describe a drug-switch strategy to achieve the best effect possible with a pair of collaterally sensitive drugs. It is numerically found, and consists of two stages.

- (Stage 1) to reach to the population makeup with balanced drug effect  $(ApB^*)$ , so the period lasts as long as  $T_{min}$  of the first drug
- (Stage 2) to give the two drugs with a proper ratio in period (represented by k or k'; see Figure
- 9) in order to keep ApB being constant at  $ApB^*$ , and switching them in a high frequency,
- represented by  $\Delta t \approx 0$




Figure 9: Diagram of the relationship between therapy duration (like  $\Delta t$ ,  $k \Delta t$ , or  $\Delta t/k'$ ) and change in ApB around  $ApB^*$ .  $\Delta t$  represents an arbitrary time interval (supposed to be small,  $\Delta t \approx 0$ ), and k represents a specific quantity corresponding to such  $\Delta t$  and parameters of DrugA and DrugB.

Both k and k' represents relative duration of DrugA compared to duration of DrugB in Stage 234 2. The explicit formulation of k can be derived from the solution of the differential equations 235 (2) by (i) evaluating the level of ApB after  $\Delta t$ -long DrugA therapy started with ApB(0) =236  $ApB^* (ApB_{\Delta t}^{DrugA})$ , and then, (ii) by measuring the time period taken to achieve  $ApB^*$  back from 237  $ApB_{\Delta t}^{DrugA}$  through DrugB therapy ( $\Delta t'$ ), and finally (iii) taking ratio between the two therapy 238 periods ( $k = \Delta t/\Delta t'$ ). k depends on drug switch frequency and model parameters,

$$k = k(\Delta t, p_A, p_B). \tag{9}$$

Such k is consistent with k', which is the ratio similarly evaluated with DrugB as first therapy and DrugA as follow-up therapy, in the optimal case of instantaneous switching,

$$\lim_{\Delta t \to 0} k(\Delta t, p_A, p_B) = \lim_{\Delta t \to 0} k'(\Delta t, p_A, p_B)$$
  
= 
$$\frac{(r_A - s_B)((r_A - s_A)(r_B - s_A) + g_A(r_A + r_B - s_A - s_B))}{(r_B - s_A)((r_B - s_B)(r_A - s_B) + g_B(r_A + r_B - s_A - s_B))} := k^*(p_A, p_B).$$
(10)

We studied how sensitive  $k^*$  (or  $f^* = k^*/(1+k^*)$ ) is over a reasonable range of non-dimentionalized  $\{p_A, p_B\}$  (see Appendix B for the detail).  $k^*$  (or  $f^*$ ) increases, as  $r_A$  and/or  $s_B$  increases and as  $s_A$ and/or  $r_B$  increases.

242




Figure 10: Comparison between dynamical trajectories of the optimal ( $T_{min}$  switch; blue curves) and a non-optimal ( $T_{max}$  switch; red curves) therapeutic strategies. Part of curves over Stage 1 and Stage 2 are drawn in gray and white backgrounds respectively. Parameters/conditions:  $\{s_A, s_B\} = \{-0.18, -0.09\}/\text{day}, \{r_A, r_B\} = \{0.008, 0.016\}/\text{day}, \{g_A, g_B\} = \{0.00075, 0.00125\}/\text{day}$  and  $\{A_R^0, B_R^0\} = \{0.1, 0.9\}$ 

Figure 10 shows examples of population curves with the optimal strategy ( $T_{min}$  switch) and one non-optimal strategy ( $T_{max}$  switch) using the same choice of parameters/conditions. The visual comparison validates the better effect of the optimal strategy than the other strategy over a range of time (see Figure 10 (a)). Figure 10 (b) shows the typical pattern of ApB in the optimal therapy compared to the other, which is monotonically changing toward  $ApB^*$  in the first stage and staying still in the second stage.

249

254

261

For the sake of practicality of clinical application, instantaneous drug switch in Stage 2 could be approximated by high frequency switching with  $\Delta t \gtrsim 0$  along with the corresponding  $k(\Delta t)$ from (9), or  $k^*$  (10) independent from  $\Delta t$ . Expectedly, the smaller  $\Delta t$  is chosen, the closer to the ideal case with  $\Delta t = 0$  (see Appendix C for the details).

Additionally, we have proved that the effect of instantaneous drug switch, with an arbitrary ratio in duration between two drugs (k), is consistent to the effect of mixed drug with relative dosage ratio which is also k (Theorem A.8 in Appendix). The theorem is used in the derivation of differential system/solution of optimal strategy (Theorem A.11 in Appendix). According to the results, in Stage 2 of optimal regimen, all types of populations,  $A_R$ ,  $B_R$  and  $A_R + B_R$ , change with a same constant proliferation rate,

$$\lambda = \frac{r_A r_B - s_A s_B}{r_A + r_B - s_A - s_B}$$

## <sup>262</sup> 4 Stochastic studies on eradication time

In previous sections we utilized an entirely deterministic model of cancer. Cancers, however, are not deterministic, and without stochasticity in our system we could not model an important part

of cancer treatment: extinction. We therefore constructed a simple individual based model using a
 Gillespie algorithm to study this aspect of cross-sensitivity.

267




Figure 11: (a) Illustration of randomly possible events: birth or death in sensitive (S) or resistant (R) cell populations and transition from sensitive to resistant type.  $\{p1, p2, p3, p4, p5\}$  represent the relative probabilities of the events occurring in the stochastic model. (b) Comparison between the stochastic process and the ODE model. The mean (thick curves) of multiple stochastic simulations (thin curves) are compared to the ODE solution (dashed curves). Parameters are  $\{s_A, r_A, g_A | s_B, r_B, g_B | A_R^0, B_R^0\} = \{-0.05, 0.005, 0.0001 | -0.05, 0.005, 0.0001 | 1000, 9000\}$ , birth rate + death rate ( $I_{stoch}$ ) = 1.0.

Our stochastic model depends not only on net proliferation rates (s, r, see Equation (1)) but also on the combination of birth rates  $(b_S, b_R)$  and death rates  $(d_S, d_R)$  where  $s = b_S - d_S$  and  $r = b_R - d_R$ . These five parameters  $(b_s, b_r, d_s, d_r, g)$  govern the probabilities of events occurring (Figure 11 (a)). The time at which one of these events occurs is determined by an exponential probability distribution, and we represent the algorithm as pseudo-code thus:

(Step 1) Initialize 
$$\{S(0), R(0)\} = \{C_S^0, C_R^0\}.$$

(Step 2) Update from t to t + dt: 276 (random number generation) 277  $rt \sim U[0, 1], re \sim U[0, 1]$ 278  $a = (b_S + d_S + g)S(t) + (b_R + d_R)R(t)$ 279  $dt = -\log(rt)/a$ 280  $\{p1, p2, p3, p4, p5\} = \{b_S S(t), d_S S(t), b_R R(t), d_R R(t), g S(t)\}/a$ 281 282 if re < p1, then S(t + dt) = S(t) + 1283 else if re < p2 + p1, then S(t + dt) = S(t) - 1284 else if re < p3 + p2 + p1, then R(t + dt) = R(t) + 1285 else if re < p4 + p3 + p2 + p1, then R(t + dt) = R(t) - 1286 else, S(t + dt) = S(t) - 1 and R(t + dt) = R(t) + 1287 288 (Step 3)  $t \leftarrow t + dt$  and repeat (Step 2) until a set time has passed or extinction has occurred. 289

290

273

275

We expanded the stochastic process for a single drug to treatment with two drugs being switched in turn, as in our ODE system. (See Appendix D, for the details of the computational code.) Figure 11 (b) shows the consistency between the mean behavior of the stochastic model and the ODE system.

Despite the generally similar patterns of population curves simulated with same  $\{s, r, g\}$ -type of parameters and initial conditions, they are significantly different in terms of elimination time if birth/death combinations are different. So, we studied elimination times simulated with different combinations of birth/death rates, with a choice of fixed proliferation rates (as well as other fixed transition rates and initial condition). We defined an index to represent different levels of birth and death rate combinations:

306

295

 $I_{stoch} = b_{I,J} + d_{I,J}$  for  $I \in \{S, R\}$  and  $J \in \{A, B\}$ 

where *I* indicates a type of sensitivity or resistance and *J* does a type of drug. Given a specific net proliferation rate  $(b_{I,J} - d_{I,J})$ , the larger the index is, the larger both birth  $(b_{I,J})$  and death  $(d_{I,J})$ rates are.




Figure 12: Comparison between stochastic simulations with different levels of birth/death combinations:  $I_{stoch} = 0.1$  (a) and  $I_{stoch} = 1.0$  (b). For each case, 20 simulated cell number histories are shown in thin curves with their median in a thick curve. Same values are used for other parameters/conditions, in both cases:  $\{s_A, r_A, g_A | s_B, r_B, g_B | A_R^0, B_R^0\} = \{-0.05, 0.005, 0.0001 | -0.05, 0.0001 | 1000, 9000\}.$ 

Increased  $I_{stoch}$  result in larger fluctuations (Figure 12 (b)), these fluctuations then increase the probability of reaching an absorbing state, in this case extinction. The relationship between  $I_{stoch}$ and extinction time is shown in Figure 13. The relationship is significant (p < 0.05 and  $r^2 = 0.1726$ with slope= -93.68 days<sup>2</sup>).

#### **5** Conclusions and discussion

The emergence of resistance to our presently best therapies is a sad, and conserved reality in the oncology clinics today. While much effort has been put into novel drug discovery to combat this, there is also a growing interest in determining optimal sequences, or cycles of drugs that induce




Figure 13: Relationship between birth-death combinations ( $I_{stoch}$ ; 0.1 to 1.0 with intervals of 0.1) and simulated extinction time in 200 replicates. Parameters are  $\{s_A, r_A, g_A | s_B, r_B, g_B | A_R^0, B_R^0\} = \{-0.05, 0.005, 0.0001 | -0.05, 0.005, 0.0001 | 1000, 9000\}$ . Regression (red line) is y = -93.68x + 414 (slope has p<0.05 and  $r^2 = 0.1726$ ).Cyan lines show mean values.

continued (or collateral) sensitivity. To study this second scenario, we proposed a simple dynamical systems model of tumor evolution in a heterogeneous tumor composed of two cell phenotypes.
While in reality, cell phenotype can be defined in many ways, here we completely describe it by
considering only sensitivity (or resistance) to a pair of collaterally sensitive drugs, which is encoded in their differential growth rates in specific conditions. While the resulting mathematical
model conveys only simple, but essential, features of cell population dynamics, it does yield analytical solutions that more complex models can not.

322

Our original motivation was to consider more complicated sequences, or cycles of drug therapy, however, the model presented herein is difficult to apply for an expanded system of more than two drugs. On the other hand, the cell classification used by other [11, 12, 21, 22, 25] considers sensitivity and resistance independently, or even specifically to a given, abstracted, genotype [26, 27]. Therefore, in case of 2 drugs, there are  $2^2 = 4$  groups, (i) sensitive to both drugs, (ii) and (iii) resistant to only one drug, and (iv) resistant to both drugs. This formulation could be expanded and applied to more than two drugs [11, 25], and we will consider it in future work.

330

341

The simplicity of our exponential growth/decay model is owing to the assumption of a constant 331 growth rate. Use of exponential growth is likely not overly inappropriate, as we are most interested 332 in the development of resistance - and resistance is typically thought to begin when tumor bur-333 den is much smaller than carrying capacity. However, the assumption might have oversimplified 334 patterns of cell growth, which is assumed to be non-exponential by others (e.g. logistic growth 335 [24, 28, 29]), due to the limited space and resource of human body for tumor growth, as well as 336 increasing levels of resistance (increasing growth rates) in the face of continued selective pres-337 sure [30]. We will consider the concept of changing growth rate in terms of time and population 338 density, and explore its effect on our analytical results (like  $T_{gap}$ ,  $ApB^*$ ,  $k^*$  and etc.) in future work. 339 340

We provided a strategy of drug-switch which can yield the theoretically best possible effect in

decreasing cell populations. The strategy is defined explicitly in terms of these parameters relevant 342 to the used drugs, so the usefulness of our analytic results are challenged by the availability of drug 343 parameters. Drug parameters for several drugs are known based on in vitro experiment or clinical 344 studies [31, 32]. However, it is not available for all drugs, and even the results measured *in vitro* 345 would likely change from one patient to the next. Because of this, we propose focusing our future 346 work on learning to parameterize models of this type from individual patient response data. Ex-347 amples of parameterizing patient response from imaging [33] as well as blood based markers [34] 348 already exist, suggesting this is a reasonable goal in the near term. 349

350

In our optimized treatment regimen we must first apply DrugA (if DrugA is better at the ini-351 tial time, i.e.,  $ApB(0) < ApB^*$ ; see Figure 8). Surprisingly the ideal treatment course switches to 352 DrugB while DrugA is still effective at reducing total population. Since treatment should ideally 353 switch before the tumor relapses our study justifies the search for techniques that either identify or 354 predict resistance mechanisms early. Our study also argues against the opposite extreme, wherein 355 resistant cells are targeted at the beginning of treatment. The preponderance of cells sensitive to 356 the standard of care makes this treatment initially ideal, and does not preclude eventual success in 357 our model. Further, the rapid tumor size reduction associated with targeting the larger, sensitive, 358 population first could be clinically meaningful. 359

360

Our stochastic model allowed us to explore the contributions of cell birth and death separately, 361 as opposed to the ODE which could only consider the net growth rate. These parameters can be 362 altered in cancer since cancer treatments have various cytostatic and cytotoxic effects, and therefore 363 different treatments can have different effects on death and birth. In our model, increasing the total 364 birth and death rate (as opposed to the net growth rate) caused extinction earlier in time (Figure 365 12, Figure 13). This can be explained by the fact that extinction is the only absorbing state in our 366 model, and therefore higher death rates determine when extinction occurs, even when birth rates 367 are also higher. Our stochastic model therefore suggests that highly cytotoxic drugs (even those 368 with correspondingly minimal cytostatic effects) are more effective at eliminating tumors, at least 369 when the tumor population is small. 370

371

Other possible ideas of future work involve comparison between different models. A recent area of debate concerns whether cycling, or directly mixing therapies is superior. In our simplified model, we show under certain regimes of (timing of) drug switching, the effect of drug cycling and drug mixing strategies are equivalent (Theorem A.8). Further exploring the ramifications of this through modeling of timing and combinations would be of value [35, 36].

377

In summary, we have presented a simple model of a heterogeneous two phenotype tumour with evolution between resistant and sensitive states. We derive exact analytic solutions for tumor response in temporally changing drug conditions and find an optimal regimen which involves drug switching after a specific, critical time point, which critically, occurs before resistance would normally be clinically evident. While our model is highly simplified, we have identified several opportunities to improve our understanding and treatment of drug resistance, and also future opportunities for new modelling endeavors.

## **385 References**

[1] C. Holohan, S. Van Schaeybroeck, D. B. Longley, and P. G. Johnston, "Cancer drug resistance: an evolving paradigm," *Nature reviews. Cancer*, vol. 13, no. 10, p. 714, 2013.

- <sup>388</sup> [2] R. J. Gillies, D. Verduzco, and R. A. Gatenby, "Evolutionary dynamics unifies carcinogenesis <sup>389</sup> and cancer therapy," *Nature reviews. Cancer*, vol. 12, no. 7, p. 487, 2012.
- [3] N. Amirouchene-Angelozzi, C. Swanton, and A. Bardelli, "Tumor evolution as a therapeutic target," *Cancer Discovery*, vol. 7, no. 8, pp. 805–817, 2017.
- <sup>392</sup> [4] M.-T. Dimanche-Boitrel, C. Garrido, and B. Chauffert, "Kinetic resistance to anticancer <sup>393</sup> agents," *Cytotechnology*, vol. 12, no. 1-3, pp. 347–356, 1993.
- [5] A. Thomas, S. El Rouby, J. C. Reed, S. Krajewski, R. Silber, M. Potmesil, and E. W. New comb, "Drug-induced apoptosis in b-cell chronic lymphocytic leukemia: relationship between
   p53 gene mutation and bcl-2/bax proteins in drug resistance.," *Oncogene*, vol. 12, no. 5,
   pp. 1055–1062, 1996.
- [6] C. Scheel and R. A. Weinberg, "Phenotypic plasticity and epithelial-mesenchymal transitions
   in cancer and normal stem cells?," *International journal of cancer*, vol. 129, no. 10, pp. 2310–2314, 2011.
- [7] D. J. Hutchison, "Cross resistance and collateral sensitivity studies in cancer chemotherapy,"
   *Advances in cancer research*, vol. 7, pp. 235–350, 1963.
- [8] A. Dhawan, D. Nichol, F. Kinose, M. E. Abazeed, A. Marusyk, E. B. Haura, and J. G. Scott,
   "Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies
   in alk mutated non-small cell lung cancer," *Scientific Reports*, vol. 7, 2017.
- [9] L. Imamovic and M. O. Sommer, "Use of collateral sensitivity networks to design drug cycling
   protocols that avoid resistance development," *Science translational medicine*, vol. 5, no. 204,
   pp. 204ra132–204ra132, 2013.
- [10] D. Nichol, J. Rutter, C. Bryant, P. Jeavons, A. Anderson, R. Bonomo, and J. Scott, "Collateral sensitivity is contingent on the repeatability of evolution," *bioRxiv*, p. 185892, 2017.
- [11] C. Tomasetti and D. Levy, "An elementary approach to modeling drug resistance in cancer,"
   *Mathematical biosciences and engineering: MBE*, vol. 7, no. 4, p. 905, 2010.
- <sup>413</sup> [12] J. Goldie and A. Coldman, "Quantitative model for multiple levels of drug resistance in clini-<sup>414</sup> cal tumors.," *Cancer treatment reports*, vol. 67, no. 10, pp. 923–931, 1983.
- [13] N. L. Komarova and D. Wodarz, "Evolutionary dynamics of mutator phenotypes in cancer,"
   *Cancer Research*, vol. 63, no. 20, pp. 6635–6642, 2003.
- <sup>417</sup> [14] J. Goldie, "Rationale for the use of alternating non-cross-resistant chemotherapy," *Cancer* <sup>418</sup> *Treat Rep*, vol. 66, pp. 439–449, 1982.
- <sup>419</sup> [15] E. Gaffney, "The application of mathematical modelling to aspects of adjuvant chemotherapy <sup>420</sup> scheduling," *Journal of mathematical biology*, vol. 48, no. 4, pp. 375–422, 2004.
- [16] E. Gaffney, "The mathematical modelling of adjuvant chemotherapy scheduling: incorporating the effects of protocol rest phases and pharmacokinetics," *Bulletin of mathematical biology*, vol. 67, no. 3, pp. 563–611, 2005.
- [17] E. A. Boston and E. A. Gaffney, "The influence of toxicity constraints in models of chemotherapeutic protocol escalation," *Mathematical medicine and biology: a journal of the IMA*,
  vol. 28, no. 4, pp. 357–384, 2011.

- [18] J. G. Scott, A. G. Fletcher, A. R. Anderson, and P. K. Maini, "Spatial metrics of tumour vas cular organisation predict radiation efficacy in a computational model," *PLoS computational biology*, vol. 12, no. 1, p. e1004712, 2016.
- [19] K. A. Rejniak, "A single-cell approach in modeling the dynamics of tumor microregions,"
   *Math. Biosci. Eng*, vol. 2, no. 3, pp. 643–655, 2005.
- [20] J.-H. Chen, Y.-H. Kuo, and H. P. Luh, "Optimal policies of non-cross-resistant chemotherapy
  on goldie and coldmans cancer model," *Mathematical biosciences*, vol. 245, no. 2, pp. 282–
  298, 2013.
- [21] A. A. Katouli and N. L. Komarova, "The worst drug rule revisited: mathematical modeling
  of cyclic cancer treatments," *Bulletin of mathematical biology*, vol. 73, no. 3, pp. 549–584,
  2011.
- I. Goldie and A. Coldman, "A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate.," *Cancer treatment reports*, vol. 63, no. 11-12, pp. 1727–1733, 1979.
- [23] A. Coldman and J. Goldie, "A model for the resistance of tumor cells to cancer chemothera peutic agents," *Mathematical Biosciences*, vol. 65, no. 2, pp. 291–307, 1983.
- <sup>443</sup> [24] P. Gerlee, "The model muddle: in search of tumor growth laws," *Cancer research*, vol. 73, no. 8, pp. 2407–2411, 2013.
- <sup>445</sup> [25] J. H. Goldie and A. J. Coldman, *Drug resistance in cancer: mechanisms and models*. Cambridge University Press, 2009.
- [26] N. L. Komarova and D. Wodarz, "Drug resistance in cancer: principles of emergence and pre vention," *Proceedings of the National Academy of Sciences of the United States of America*,
   vol. 102, no. 27, pp. 9714–9719, 2005.
- [27] D. Nichol, P. Jeavons, A. G. Fletcher, R. A. Bonomo, P. K. Maini, J. L. Paul, R. A. Gatenby,
  A. R. Anderson, and J. G. Scott, "Steering evolution with sequential therapy to prevent the
  emergence of bacterial antibiotic resistance," *PLoS computational biology*, vol. 11, no. 9,
  p. e1004493, 2015.
- <sup>454</sup> [28] S. J. Berry, D. S. Coffey, P. C. Walsh, and L. L. Ewing, "The development of human benign <sup>455</sup> prostatic hyperplasia with age," *The Journal of urology*, vol. 132, no. 3, pp. 474–479, 1984.
- [29] N. C. Atuegwu, L. R. Arlinghaus, X. Li, A. B. Chakravarthy, V. G. Abramson, M. E. Sanders,
  and T. E. Yankeelov, "Parameterizing the logistic model of tumor growth by dw-mri and
  dce-mri data to predict treatment response and changes in breast cancer cellularity during
  neoadjuvant chemotherapy," *Translational oncology*, vol. 6, no. 3, pp. 256–264, 2013.
- [30] J. Scott and A. Marusyk, "Somatic clonal evolution: A selection-centric perspective," *Biochimica et Biophysica Acta (BBA)-Reviews on Cancer*, vol. 1867, no. 2, pp. 139–150, 2017.
- [31] T. L. Jackson and H. M. Byrne, "A mathematical model to study the effects of drug resistance and vasculature on the response of solid tumors to chemotherapy," *Mathematical biosciences*, vol. 164, no. 1, pp. 17–38, 2000.

- [32] W. H. Wilson, J. Teruya-Feldstein, T. Fest, C. Harris, S. M. Steinberg, E. S. Jaffe, and M. Raffeld, "Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-hodgkin9s lymphomas," *Blood*, vol. 89, no. 2, pp. 601–609, 1997.
- [33] K. R. Swanson, R. C. Rockne, J. Claridge, M. A. Chaplain, E. C. Alvord, and A. R. Anderson,
  "Quantifying the role of angiogenesis in malignant progression of gliomas: in silico modeling integrates imaging and histology," *Cancer research*, vol. 71, no. 24, pp. 7366–7375, 2011.
- [34] B. Werner, J. G. Scott, A. Sottoriva, A. R. Anderson, A. Traulsen, and P. M. Altrock, "The cancer stem cell fraction in hierarchically organized tumors can be estimated using mathematical modeling and patient-specific treatment trajectories," *Cancer research*, vol. 76, no. 7, pp. 1705–1713, 2016.
- [35] R. E. Beardmore, R. Peña-Miller, F. Gori, and J. Iredell, "Antibiotic cycling and antibiotic mixing: which one best mitigates antibiotic resistance?," *Molecular biology and evolution*, vol. 34, no. 4, pp. 802–817, 2017.
- <sup>479</sup> [36] R. Pena-Miller and R. Beardmore, "Antibiotic cycling versus mixing: the difficulty of using <sup>480</sup> mathematical models to definitively quantify their relative merits.," 2010.

### **481** Appendix A Derivations of explicit expressions

491 **Proposition A.1.** Under the therapy with Drug A,

$$V'(t) = \mathbb{D}_A V(t), \ V(t_0 + \Delta t) = \mathbb{M}_A(\Delta t) \ V(t_0).$$

<sup>493</sup> Under the therapy with Drug B,

494

$$V'(t) = \mathbb{D}_B V(t), \ V(t_0 + \Delta t) = \mathbb{M}_B(\Delta t) \ V(t_0).$$

#### **A95** A.1 Differential system of instantaneous drug switch

**Proposition A.2.** Both  $A_R$  and  $B_R$  are monotonic functions under either therapy. Under the presence of Drug A,  $A_R$  is increasing, and  $B_R$  is decreasing. And, under the presence of Drug B,  $A_R$  is decreasing, and  $B_R$  is increasing.

499 **Proposition A.3.**  $\mathbb{A}_{\epsilon}|_{\epsilon=0} = \mathbb{B}_{\epsilon}|_{\epsilon=0} = I_2$  for all  $0 \leq f \leq 1$ 

**Proposition A.4.** 
$$\left. \frac{d}{d\epsilon} \mathbb{A}_{\epsilon} \right|_{\epsilon=0} = f \mathbb{D}_{A}, \left. \frac{d}{d\epsilon} \mathbb{B}_{\epsilon} \right|_{\epsilon=0} = (1-f) \mathbb{D}_{B} \text{ for all } 0 \leq f \leq 1$$

Lemma A.5. 
$$\lim_{\epsilon \to 0} \frac{\mathbb{B}_{\epsilon} \mathbb{A}_{\epsilon} - I_2}{\epsilon} = f \mathbb{D}_A + (1 - f) \mathbb{D}_B$$
 for all  $0 \le f \le 1$ 

Proof.

$$\lim_{\epsilon \to 0} \frac{\mathbb{B}_{\epsilon} \mathbb{A}_{\epsilon} - I_2}{\epsilon} = \lim_{\epsilon \to 0} \frac{\frac{d}{d\epsilon} (\mathbb{B}_{\epsilon} \mathbb{A}_{\epsilon} - I_2)}{\frac{d}{d\epsilon} \epsilon}$$
 (by L'Hospital's Rule)  
$$= \lim_{\epsilon \to 0} \frac{\frac{d\mathbb{B}_{\epsilon}}{d\epsilon} \mathbb{A}_{\epsilon} + \mathbb{B}_{\epsilon} \frac{d\mathbb{A}_{\epsilon}}{d\epsilon}}{1}$$
$$= f \mathbb{D}_A + (1 - f) \mathbb{D}_B$$
 (by Propositions A.3 - A.4)

502

Lemma A.6.  $\lim_{\epsilon \to 0} \frac{(\mathbb{B}_{\epsilon} \mathbb{A}_{\epsilon})^n - I_2}{n \epsilon} = f \mathbb{D}_A + (1 - f) \mathbb{D}_B \text{ for any positive integer, } n, \text{ and for all}$ 

 $\begin{array}{l} \textit{Proof. Let } F(n)\coloneqq \lim_{\epsilon\to 0} \frac{(\mathbb{B}_{\epsilon}\mathbb{A}_{\epsilon})^n-I_2}{n\,\epsilon} \text{ and } L\coloneqq f\,\mathbb{D}_A+(1-f)\mathbb{D}_B.\\ \text{Then, we need to prove that } F(n)=L \text{ for } n=1,2,3,\ldots\\ \text{If } n=1, \end{array}$ 

$$F(n) = F(1) = L$$
 (by Lemma A.5)

Otherwise, if  $n \ge 2$  and F(m) = L for all  $1 \le m \le n - 1$ ,

$$F(n) = \lim_{\epsilon \to 0} \frac{(\mathbb{B}_{\epsilon} \mathbb{A}_{\epsilon})^n - I_2}{n \epsilon}$$

$$= \lim_{\epsilon \to 0} \frac{((\mathbb{B}_{\epsilon} \mathbb{A}_{\epsilon})^{n-1} - I_2)(\mathbb{B}_{\epsilon} \mathbb{A}_{\epsilon}) + (\mathbb{B}_{\epsilon} \mathbb{A}_{\epsilon} - I_2)}{n \epsilon}$$

$$= \frac{n-1}{n} \lim_{\epsilon \to 0} \frac{((\mathbb{B}_{\epsilon} \mathbb{A}_{\epsilon})^{n-1} - I_2)(\mathbb{B}_{\epsilon} \mathbb{A}_{\epsilon})}{(n-1) \epsilon} + \frac{1}{n} \lim_{\epsilon \to 0} \frac{\mathbb{B}_{\epsilon} \mathbb{A}_{\epsilon} - I_2}{\epsilon}$$

$$= \frac{n-1}{n} F(n-1) + \frac{1}{n} F(1)$$

$$= \frac{n-1}{n} L + \frac{1}{n} L$$
(by the inductive assumption)
$$= L$$

<sup>505</sup> Therefore, proved.

**Lemma A.7.**  $\lim_{\epsilon \to 0} \frac{\mathbb{A}_{\epsilon}(\mathbb{B}_{\epsilon}\mathbb{A}_{\epsilon})^{n} - I_{2}}{(n+f) \epsilon} = \frac{(n+1)f}{n+f} \mathbb{D}_{A} + \frac{n(1-f)}{n+f} \mathbb{D}_{B}$  for any positive integer, n, and for all  $0 \le f \le 1$ 

*Proof.* Using mathematical induction, if n=1,

$$\begin{split} &\lim_{\epsilon \to 0} \frac{\mathbb{A}_{\epsilon}(\mathbb{B}_{\epsilon}\mathbb{A}_{\epsilon}) - I_{2}}{(1+f) \epsilon} \\ &= \frac{1}{1+f} \lim_{\epsilon \to 0} \frac{\mathbb{A}_{\epsilon}(\mathbb{B}_{\epsilon}\mathbb{A}_{\epsilon} - I_{2}) + (\mathbb{A}_{\epsilon} - I_{2})}{\epsilon} \\ &= \frac{1}{1+f} \left[\lim_{\epsilon \to 0} \mathbb{A}_{\epsilon} \lim_{\epsilon \to 0} \frac{\mathbb{B}_{\epsilon}\mathbb{A}_{\epsilon} - I_{2}}{\epsilon} + \lim_{\epsilon \to 0} \frac{\mathbb{A}_{\epsilon} - I_{2}}{\epsilon} \right] \\ &= \frac{1}{1+f} \left[I_{2}(f \mathbb{D}_{A} + (1-f)\mathbb{D}_{B}) + \frac{d}{d\epsilon}\mathbb{A}_{\epsilon} \Big|_{\epsilon=0}\right] \qquad \text{(by Proposition A.3 and Lemma A.5)} \\ &= \frac{1}{1+f} \left[(f \mathbb{D}_{A} + (1-f)\mathbb{D}_{B}) + k \mathbb{D}_{A}\right] \qquad \qquad \text{(by Proposition A.4)} \\ &= \frac{2f}{1+f}\mathbb{D}_{A} + \frac{1-f}{1+f}\mathbb{D}_{B} \qquad \qquad \text{The equality is true for } n = 1 \end{split}$$

If  $n \ge 2$ , and the equality works for all integers  $1 \le m \le n - 1$ ,

$$=\frac{(n+1)f}{n+f}\mathbb{D}_A + \frac{n(1-f)}{n+f}\mathbb{D}_B$$
 (The equality is true for  $n \ge 2$ )

<sup>508</sup> Therefore, proved.

**Theorem A.8.** If Drug A and Drug B are prescribed in turn with relative intensity f and 1 - f, and are switched instantaneously, V obeys

$$\frac{dV}{dt} = (f \, \mathbb{D}_A + (1-f)\mathbb{D}_B)V$$

*Proof.* For any time point  $t_0$ , let us define  $V_{\epsilon}(t)$  as a vector-valued function of  $A_R(t)$  and  $B_R(t)$  describing cell population dynamics under periodic therapy started on  $t_0$  with DrugA assigned on  $t_0+m \epsilon \leq t < t_0+(m+f)\epsilon$  and DrugB on  $t_0+(m+f)\epsilon \leq t < t_0+(m+1)\epsilon$  for m = 0, 1, 2, 3, ... Then, by Proposition A.1 and the definitions of A and B,

$$V_{\epsilon}(t_0 + m \epsilon) = (\mathbb{B}_{\epsilon} \mathbb{A}_{\epsilon})^m V(t_0), \quad V_{\epsilon}(t_0 + (m + f)\epsilon) = \mathbb{A}_{\epsilon}(\mathbb{B}_{\epsilon} \mathbb{A}_{\epsilon})^m V(t_0) \quad \cdots (*1)$$

where  $V(t_0) = \begin{pmatrix} A_R(t_0) \\ B_R(t_0) \end{pmatrix}$ . And,  $V_0(t)$  represents instantaneous drug switch. For any  $\Delta t > 0$  and any positive integer *n*, there exists  $\epsilon = \epsilon(n, \Delta t)$  such that

$$\frac{\Delta t}{n+1} < \epsilon \le \frac{\Delta t}{n}$$
 or  $1 \le \frac{\Delta t}{n \epsilon} < 1 + \frac{1}{n}$ .

Then by the squeeze theorem,

$$\lim_{\Delta t \to 0} \epsilon(n, \Delta t) = 0 \text{ for any positive integer } n, \text{ and } \lim_{n \to \infty} \frac{\Delta t}{n \epsilon(n, \Delta t)} = 1 \text{ for any } \Delta t > 0. \quad \cdots (*2)$$

For such  $\Delta t$ , n and  $\epsilon(n, \Delta t)$ ,  $V_{\epsilon}(t_0 + \Delta t)$  is bounded, since local extrema can occur only at which drugs switch by Proposition A.2. That is,

$$\min \left[ V_{\epsilon}(t_0 + n \epsilon), V_{\epsilon}(t_0 + (n + f)\epsilon), V_{\epsilon}(t_0 + (n + 1)\epsilon) \right] \leq V_{\epsilon}(t_0 + \Delta t)$$
  
$$\leq \max \left[ V_{\epsilon}(t_0 + n \epsilon), V_{\epsilon}(t_0 + (n + f)\epsilon), V_{\epsilon}(t_0 + (n + 1)\epsilon) \right], \qquad \cdots (*3)$$

Also,

$$\begin{split} \lim_{\Delta t \to 0} \frac{\lim_{n \to \infty} V_{\epsilon(n,\Delta t)}(t_0 + n \ \epsilon(n,\Delta t)) - V(t_0)}{\Delta t} \\ &= \lim_{\Delta t \to 0} \lim_{n \to \infty} \frac{(\mathbb{B}_{\epsilon} \mathbb{A}_{\epsilon})^n - I_2}{\Delta t} V(t_0) \qquad (by \ (*1)) \\ &= \frac{\lim_{\Delta t \to 0} \lim_{n \to \infty} \left[ (\mathbb{B}_{\epsilon} \mathbb{A}_{\epsilon})^n - I_2 \right] / (n \ \epsilon)}{\lim_{\Delta t \to 0} \lim_{n \to \infty} \Delta t / (n \ \epsilon)} V(t_0) \\ &= \frac{\lim_{n \to \infty} \left[ \lim_{\Delta t \to 0} \left[ (\mathbb{B}_{\epsilon} \mathbb{A}_{\epsilon})^n - I_2 \right] / (n \ \epsilon) \right]}{\lim_{\Delta t \to 0} \left[ \lim_{n \to \infty} \Delta t / (n \ \epsilon) \right]} V(t_0) \\ &= \frac{\lim_{n \to \infty} \left[ \lim_{\epsilon \to 0} \left[ (\mathbb{B}_{\epsilon} \mathbb{A}_{\epsilon})^n - I_2 \right] / (n \ \epsilon) \right]}{\lim_{\Delta t \to 0} 1} V(t_0) \qquad by \ (*2) \\ &= \lim_{n \to \infty} \left[ f \ \mathbb{D}_A + (1 - f) \mathbb{D}_B \right] V(t_0) \qquad (by \ Lemma \ A.6) \\ &= (f \ \mathbb{D}_A + (1 - f) \mathbb{D}_B) V(t_0). \qquad \cdots \ (*4) \end{split}$$

And,

$$\begin{split} \lim_{\Delta t \to 0} \frac{\lim_{n \to \infty} V_{\epsilon(n,\Delta t)}(t_0 + (n+f) \ \epsilon(n,\Delta t)) - V(t_0)}{\Delta t} \\ &= \lim_{\Delta t \to 0} \lim_{n \to \infty} \frac{A_{\epsilon}(\mathbb{B}_{\epsilon} \mathbb{A}_{\epsilon})^n - I_2}{\Delta t} V(t_0) \\ &= \frac{\lim_{\Delta t \to 0} \lim_{n \to \infty} [\mathbb{A}_{\epsilon}(\mathbb{B}_{\epsilon} \mathbb{A}_{\epsilon})^n - I_2] / ((n+f) \ \epsilon)}{\lim_{\Delta t \to 0} \lim_{n \to \infty} \Delta t / ((n+f) \ \epsilon)} V(t_0) \\ &= \frac{\lim_{n \to \infty} [\lim_{\Delta t \to 0} [(\mathbb{B}_{\epsilon} \mathbb{A}_{\epsilon})^n - I_2] / ((n+f) \ \epsilon)]}{\lim_{\Delta t \to 0} [(\mathbb{B}_{\epsilon} \mathbb{A}_{\epsilon})^n - I_2] / ((n+f) \ \epsilon)]} V(t_0) \\ &= \frac{\lim_{n \to \infty} [\lim_{n \to \infty} [\mathbb{I} \mathbb{I} \mathbb{A}_{\epsilon} \mathbb{I}^n - I_2] / ((n+f) \ \epsilon)]}{\lim_{\Delta t \to 0} 1} V(t_0) \\ &= \lim_{n \to \infty} \left[ \frac{(n+1)f}{n+f} \ \mathbb{D}_A + \frac{n(1-f)}{n+f} \ \mathbb{D}_B \right] V(t_0) \\ &= (f \ \mathbb{D}_A + (1-f) \mathbb{D}_B) V(t_0) \\ & \cdots (*5) \end{split}$$

Similar to (\*4),

$$\lim_{\Delta t \to 0} \frac{\lim_{n \to \infty} V_{\epsilon(n,\Delta t)}(t_0 + (n+1) \epsilon(n,\Delta t)) - V(t_0)}{\Delta t} = (f \mathbb{D}_A + (1-f)\mathbb{D}_B)V(t_0) \quad \cdots (*6)$$

$$\min \left[ \lim_{\Delta t \to 0} \frac{\lim_{n \to \infty} V_{\epsilon}(t_{0} + n \epsilon) - V(t_{0})}{\Delta t}, \lim_{\Delta t \to 0} \frac{\lim_{n \to \infty} V_{\epsilon}(t_{0} + (n + f) \epsilon) - V(t_{0})}{\Delta t}, \right]$$
$$\lim_{\Delta t \to 0} \frac{\lim_{n \to \infty} V_{\epsilon}(t_{0} + (n + 1) \epsilon) - V(t_{0})}{\Delta t} \right] = \max \left[ \lim_{\Delta t \to 0} \frac{\lim_{n \to \infty} V_{\epsilon}(t_{0} + n \epsilon) - V(t_{0})}{\Delta t}, \right]$$
$$\lim_{\Delta t \to 0} \lim_{\Delta t \to 0} \frac{\lim_{n \to \infty} V_{\epsilon}(t_{0} + (n + f) \epsilon) - V(t_{0})}{\Delta t}, \lim_{\Delta t \to 0} \frac{\lim_{n \to \infty} V_{\epsilon}(t_{0} + (n + 1) \epsilon) - V(t_{0})}{\Delta t} \right]$$
$$= (f \mathbb{D}_{A} + (1 - f)\mathbb{D}_{B})V(t_{0}) \qquad \cdots (*7)$$

Then, by (\*3), (\*7) and the squeeze theorem, 

$$\left. \frac{d}{dt} V_0 \right|_{t=t_0} = \lim_{\Delta t \to 0} \frac{\lim_{n \to \infty} V_{\epsilon}(t_0 + \Delta t) - V(t_0)}{\Delta t} = (f \ \mathbb{D}_A + (1 - f) \mathbb{D}_B) V(t_0)$$

Therefore, 

$$\frac{dV}{dt} = (f \mathbb{D}_A + (1-f)\mathbb{D}_B)V$$

#### A.2 Population dynamics with the optimal regimen

**Lemma A.9.**  $\left\{ \frac{r_A r_B - s_A s_B}{r_A + r_B - s_A - s_B}, \begin{pmatrix} ApB^* \\ 1 \end{pmatrix} \right\}$  is an eigen pair of  $f^* \mathbb{D}_A + (1 - f^*)\mathbb{D}_B$  with  $ApB^*$  and  $f^*$  from (8), (10) and (13). 

From 
$$F$$
 Let  $\mathbb{D}^* := f^* \mathbb{D}_A + (1 - f^*) \mathbb{D}_B$ , and  $\lambda = \frac{r_A r_B - s_A s_B}{r_A + r_B - s_A - s_B}$ . Then,  
 $\mathbb{D}^* - \lambda I_2 = C_1 \begin{pmatrix} C_2 U^T \\ C_3 U^T \end{pmatrix}$ ,

where 
$$U = \begin{pmatrix} 1 \\ -ApB^* \end{pmatrix}$$
 along with

$$\begin{split} C_1 &= -(g_A(r_A - s_B) + g_B(r_B - s_A) + (r_B - s_A)(r_A - s_B))(r_A + r_B - s_A - s_B)/(r_A - s_B), \\ C_2 &= g_A((r_A - s_B)(r_B - s_B) + g_B(r_A + r_B - s_A - s_B), \\ C_3 &= -g_B((r_B - s_A)(r_A - s_A) + g_A(r_A + r_B - s_A - s_B)). \end{split}$$

Since  $U^T V = 0$  where  $V = ((r_B - s_A)/(r_A - s_B), 1)^T$ ,  $(\lambda, V)$  is an eigen pair of  $\mathbb{D}^*$ . 

**Theorem A.10.** In Stage 2 of the optimal strategy, both  $A_R$  and  $B_R$  changes with a constant net-proliferation rate, 

$$\lambda = \frac{r_A r_B - s_A s_B}{r_A + r_B - s_A - s_B}$$

*Proof.* Without loss of generosity, let us prove it only when  $ApB(0) < ApB^*$ . 

If  $ApB(0) < ApB^*$ , DrugA has a better effect initially. So following the optimal therapy scheduling, DrugA is assigned alone at the beginning as long as  $T_{min}^A = T_{min}(p_A, p_B, ApB(0))$  (Stage 1), and then Stage 2 starts at  $T_{min}^A$  with initial condition

$$V(T_{min}^{A}) = \mathbb{M}_{A}(T_{min}^{A})V(0) = C\left(\begin{array}{c}ApB^{*}\\1\end{array}\right) \qquad \cdots (*1)$$

where 
$$C = \frac{P(0)}{1 + ApB(0)} \left( \frac{(r_A - s_A)(r_B - s_A) + g_A(r_A + r_B - s_A - s_B)}{(r_A - s_B)(g_A + ApB(0)(g_A + r_A - s_A))} \right)^{-\frac{g_A - s_A}{g_A + r_A - s_A}}$$

By Theorem A.8, in Stage 2, V(t) obeys

$$\frac{dV}{dt} = \mathbb{D}^*V, \text{ where } \mathbb{D}^* = f^*\mathbb{D}_A + (1 - f^*)\mathbb{D}_B \qquad \cdots (*2)$$

<sup>532</sup> By Lemma A.9,  $V(T_{min}^A)$  is an eigenvector of  $\mathbb{D}^*$  with the corresponding eigenvalue,  $\lambda$ . Then, <sup>533</sup> the solution of (\*2) with the initial value (\*1) is

531

 $V(t + T^A_{min}) = e^{\lambda t} V(T^A_{min}).$ 

535

**Theorem A.11.** With optimal therapy utilizing DrugA and DrugB, V obeys the following equations and solutions.

540

539 If  $ApB(0) < ApB^*$ ,

$$\frac{dV}{dt} = \begin{cases} \mathbb{D}_A V & \text{if } 0 \le t \le T_{min}^A \\ \lambda V & \text{if } t > T_{min}^A \end{cases} \text{ and } V(t) = \begin{cases} \mathbb{M}_A(t)V(0) & \text{if } 0 \le t \le T_{min}^A \\ e^{\lambda (t-T_{min}^A)}V(T_{min}^A) & \text{if } t > T_{min}^A \end{cases}$$

Similarly if 
$$ApB(0) \ge ApB^*$$

$$\frac{dV}{dt} = \begin{cases} \mathbb{D}_B V & \text{if } 0 \le t \le T_{\min}^B \\ \lambda V & \text{if } t > T_{\min}^B \end{cases} \text{ and } V(t) = \begin{cases} \mathbb{M}_B(t)V(0) & \text{if } 0 \le t \le T_{\min}^B \\ e^{\lambda (t - T_{\min}^B)}V(T_{\min}^B) & \text{if } t > T_{\min}^B \end{cases}$$

543 *Proof.* Straightforward, by Theorem A.10

#### 544 Appendix B Sensitivity analysis on optimal scheduling

The two determinant quantities of optimal control scheduling are (i) the duration of the first stage ( $T_{min}^1$ ), and (ii) the relative intensity between two drugs in the second stage ( $k^*$  or  $f^*$ ). Here, we show sensitivity analysis on the quantities related to them over a range of model parameters.

548

550

Using  $g_1$ , we non-dimentionalize all the values, like

$$\{\overline{s_1}, \overline{r_1} | \overline{s_2}, \overline{r_2}\} := \frac{1}{g_1} \{s_1, r_1 | s_2, r_2\}$$
 and  $\overline{T_{gap}} := g_1 T_{gap}$ 

551 then,

$$\overline{T_{gap}}(\{\overline{s_1}, \overline{r_1}\}, \{\overline{s_2}, \overline{r_2}\}) := \frac{\ln\left[\frac{(1-\overline{s_1})(\overline{r_1} - \overline{s_1})(\overline{r_1} - \overline{s_2})}{\overline{r_1}((\overline{r_1} - \overline{s_1})(\overline{r_2} - \overline{s_1}) + (\overline{r_1} + \overline{r_2} - \overline{s_1} - \overline{s_2}))\right]}{1 + \overline{r_1} - \overline{s_1}}$$
(11)

In general, cells mutate in a slower way than they proliferate (ref), so we ran sensitivity analysis on  $T_{gap}$  for all  $a \gg 1$  for  $a \in \{-\overline{s_1}, -\overline{s_2}, \overline{r_1}, \overline{r_2}\}$ . Figure 14 shows  $T_{gap}$  over the range of  $20 \le -\overline{s_1}, -\overline{s_2}, \overline{r_1}, \overline{r_2} \le 100$ . So, under the assumption that  $g_1 \ll \min\{-s_1, -s_2, r_1, r_2\}$ ,

555 
$$T_{gap}(\{s_1, r_1\}, \{s_2, r_2\}) \approx \frac{\ln\left[\frac{-s_1(r_1 - s_2)}{r_1(r_2 - s_1)}\right]}{r_1 - s_1},$$

<sup>556</sup> which approximate the contour curves of Figure 14.




Figure 14: Contour maps of  $T_{gap}$  over ranges of  $20 \le a \le 100$  for  $a \in \{-s_1, -s_2, r_1, r_2\}$  and  $r_1r_2 < s_1s_2$  (Condition (6))

Regarding the regulated intensities among the two drugs,  $k^*$ , we assumed that  $g_1 \approx g_2 := g$ , similarly assuming that they are both much smaller than  $\{-s_1, -s_2, r_1, r_2\}$ . Then we normalized all the parameters with the unit of g, like

 $\{\overline{s_1}, \overline{r_1} | \overline{s_2}, \overline{r_2}\} := \frac{1}{g} \{s_1, r_1 | s_2, r_2\}.$ 

 $_{562}$   $k^*$  can be rewritten in terms of the dimensionless parameters.

561

$$k^*(\{\overline{s_1}, \overline{r_1}\}, \{\overline{s_2}, \overline{r_2}\}) = \frac{(\overline{r_1} - \overline{s_2})((\overline{r_1} - \overline{s_1})(\overline{r_2} - \overline{s_1}) + (\overline{r_1} + \overline{r_2} - \overline{s_1} - \overline{s_2}))}{(\overline{r_2} - \overline{s_1})((\overline{r_2} - \overline{s_2})(\overline{r_1} - \overline{s_2}) + (\overline{r_1} + \overline{r_2} - \overline{s_1} - \overline{s_2}))}$$
(12)

<sup>563</sup> In sensitivity analysis, we use

567

$$f^* := \frac{k^*}{1+k^*},\tag{13}$$

which represents intensity fraction of initially better drug out of total therapy. We evaluated  $f^*$ over the same ranges of  $\{s_1, s_2, r_1, r_2\}$  like the previous exercise. (see Figure 15) Over the ranges,  $\max\{g_1, g_2\} \ll \min\{-s_1, -s_2, r_1, r_2\}$ , so  $k^*$  and  $f^*$  can be approximated by simpler forms.

$$k^* \approx \frac{r_1 - s_1}{r_2 - s_2}$$
 and  $f^* \approx \frac{r_1 - s_1}{r_1 + r_2 - s_1 - s_2}$ 




Figure 15: Contour maps of  $f^*$  over ranges of  $20 \le a \le 100$  for  $a \in \{-s_1, -s_2, r_1, r_2\}$  and  $r_1r_2 < s_1s_2$  (Condition (6))

# Appendix C Clinical implementation of instantaneous switch in the optimal strategy

In clinical practice, the instantaneous drug-switch which is proposed in this research to apply in the 570 second stage of the optimal control is not implementable. Therefore, we studied similar schedules 571 to the optimal case, and compared the therapy effects between the different schedules of admin-572 istrations. In the "similar" schedules, the first stage with an initial drug remained same to the 573 optimal schedule, but the second part of instantaneous switch (with  $\Delta t = 0$ ) has been modified 574 into fast switch ( $\Delta t \gtrsim 0$ ). Figure 16 shows how the effect on population with instantaneous switch 575  $(\Delta t = 0)$  and fast switches (multiple choices of  $\Delta t \gtrsim 0$ ) are different for a choice of drug parameter 576 values. Expectedly, the smaller  $\Delta t$  is chosen, the closer to the ideal case of therapy effect. And, 577 a choice of reasonably small  $\Delta t$  (like 1 day or 3 days) results in the outcome quite close to the 578 optimal scenario. 579

#### 580

584

We simulated same exercise with  $k^*$  (from (10)) instead of  $k(\Delta t)$  modulated by  $\Delta t$  (Figure 17). Only invisibly small differences has been observed between Figure 16 and Figure 17, which justifies general usage of  $k^*$  independent from  $\Delta t$ .




Figure 16: Graphs of regular drug switch in Stage 2 with different  $\{\Delta t, k(\Delta t, p_A, p_B)\}$ :  $\Delta t = 1$  day (blue),  $\Delta t = 4$  days (red),  $\Delta t = 7$  days (green), and  $\Delta t = 10$  days (magenta). Parameters/conditions:  $p_A = \{-0.18, 0.008, 0.00075\}/day$ ,  $p_B = \{-0.9, 0.016, 0.00125\}/day$  and  $\{A_R^0, B_R^0\} = \{0.1, 0.9\}$  (a) Time histories of total populations,  $C_P^n$  for  $n \in \{1, 4, 7, 10\}$  days (b) Differences between the optimal population history  $C_P^*$ , (i.e., when  $\Delta t = 0$ ) and each cases with positive  $\Delta t$ . (i.e.,  $C_P^n - C_P^*$ ). The inside smaller plots are same types of graphs with the bigger graphs, and show enlargement of interesting ranges.




Figure 17: Graphs of regular drug switch in Stage 2 with different  $\{\Delta t\}$  and fixed  $k^*$  from 10:  $\Delta t = 1$  day (blue),  $\Delta t = 4$  days (red),  $\Delta t = 7$  days (green), and  $\Delta t = 10$  days (magenta). Parameters/conditions:  $p_A = \{-0.18, 0.008, 0.00075\}/\text{day}, p_B = \{-0.9, 0.016, 0.00125\}/\text{day}$  and  $\{A_R^0, B_R^0\} = \{0.1, 0.9\}$  (a) Time histories of total populations,  $C_P^n$  for  $n \in \{1, 4, 7, 10\}$  days (b) Differences between the optimal population history  $C_P^*$ , (i.e., when  $\Delta t = 0$ ) and each cases with positive  $\Delta t$ . (i.e.,  $C_P^n - C_P^*$ ). The inside smaller plots are same types of graphs with the bigger graphs, and show enlargement of interesting ranges.

## **585** Appendix D Stochastic simulation codes

<sup>586</sup> The computational code written in Python will be provided at *Github* (https://github.com/nryoon12/Optimal-

<sup>587</sup> Therapy-Scheduling-Based-on-a-Pair-of-Collaterally-Sensitive-Drugs).